Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Matsupexole - Kissei Pharmceutical

Next Previous
Drug Profile

Matsupexole - Kissei Pharmceutical

Alternative Names: AM006; KDT-3594

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer AffaMed Therapeutics; Kissei Pharmaceutical
  • Class Amides; Amines; Antiparkinsonians; Dimethylamines; Ethylenediamines; Nitriles; Quinolines; Small molecules; Thiophenes; Urea compounds
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 28 Aug 2025 Chemical structure information added.
  • 06 Sep 2021 Kissei Pharmaceutical completes a phase II trial in Parkinson's disease (In adults, In elderly) in Japan (PO) (NCT04867551)
  • 04 Aug 2021 Phase-II clinical trials in Parkinson's disease in China (PO) (Kissei Pharmaceutical pipeline, August 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top